NCT00565370View on ClinicalTrials.gov

Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Advanced Gastric Cancer
Interventions
DRUG

Capecitabine, Cisplatin, Sorafenib

Capecitabine ( ) mg/m2 bid D1-D15 Cisplatin 80 mg/m2 D1 Sorafenib ( ) mg bid PO daily every 3 weeks

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT00565370 - Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP | Biotech Hunter | Biotech Hunter